



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/43, 9/50, 9/20</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/35672</b> <b>(43) International Publication Date:</b> 20 August 1998 (20.08.98)
<b>(21) International Application Number:</b> PCT/EP98/00811 <b>(22) International Filing Date:</b> 10 February 1998 (10.02.98)  <b>(30) Priority Data:</b> 9703099.3 14 February 1997 (14.02.97) GB 9703100.9 14 February 1997 (14.02.97) GB 9703101.7 14 February 1997 (14.02.97) GB  <b>(71) Applicants (for all designated States except US):</b> SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES [FR/FR]; 6, esplanade Charles de Gaulle, F-92731 Nanterre Cedex (FR). SMITHKLINE BEECHAM S.A. [ES/ES]; Calle Valle de la Fuenfria, 3, E-28034 Madrid (ES). SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MENTION, Jacky, Andre, Gustave [FR/FR]; SmithKline Beecham Laboratoires Pharmaceutiques, Z.I. de la Peynnière, Boite postale 2, F-53101 Mayenne Cedex (FR). SANROMA BORDALLO, Jose, Luis [ES/ES]; SmithKline Beecham S.A. Pharmaceuticals, Poligono Industrial de Toledo, E-45007 Toledo (ES). STORM, Kevin [GB/US]; SmithKline Beecham Pharma-		ceuticals, Bristol Industrial Park, Weaver Pike, Bristol, TN 37620 (US).  <b>(74) Agent:</b> CONNELL, Anthony, Christopher; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PHARMACEUTICAL FORMULATIONS COMPRISING AMOXOCYLLIN AND CLAVULANATE		
<b>(57) Abstract</b>  Novel co-amoxiclav formulations are described, having reduced weight compared to existing formulations, as well as formulations comprising amoxycillin and potassium clavulanate in a ratio of 8:1 and formulations prepared from granulates of amoxycillin and granulates of amoxycillin and clavulanate.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE

The present invention relates to novel formulations comprising amoxycillin and clavulanate (co-amoxiclav), to processes for their preparation and their use in therapy.

5

The product co-amoxiclav is marketed by SmithKline Beecham as Augmentin for treating bacterial infections. It comprises a combination of the  $\beta$ -lactam antibacterial agent amoxycillin (present as the trihydrate) and the  $\beta$  lactamase inhibitor clavulanic acid (present as the potassium salt). Various formulations, for instance tablets, capsules, 10 powders (for reconstitution into aqueous syrups) and sachets containing free flowing granules, are provided, containing different ratios of amoxycillin and clavulanic acid. Thus, tablets and powders (for reconstitution into aqueous syrups) are available comprising amoxycillin and clavulanic acid in ratios of 2:1, 4:1 and 7:1, whilst sachets are available with the same ratios, as well as 8:1 (Augmentin, SmithKline Beecham, France, 15 'poudre pour suspension buvable a 100mg/ml nourisson', comprising 100mg amoxycillin and 12.5mg clavulanate). This leads to a complexity in the manufacturing process as each product with a different ratio is prepared separately, by blending together the different amounts of amoxycillin and clavulanate at an early stage of the process.

20 In addition, clavulanate has been blended with a diluent, conventionally in a 1:1 ratio, for safer storage and transportation. This has been silica gel (for instance the product Syloid AL-1) for non-tablet formulations and microcrystalline cellulose (for instance the product Avicel) for tablet formulations, adding to further complexity in the manufacturing process.

25 There therefore remains the need to devise more efficient manufacturing processes, to reduce complexity and improve the economics of the process. It has now been found that this can be achieved by the use of a common intermediate granulate comprising a fixed ratio of amoxycillin and clavulanate, with the differing ratios in the final formulation then being achieved by adding in appropriate amounts of amoxycillin at a later stage in the 30 process. Formulations having granulates comprising amoxycillin and clavulanate are described in GB 2 005 538-A (Beecham Group), WO 95/28927 (SmithKline Beecham) and WO 95/25516 (SmithKline Beecham). There is however no suggestion of combining granulates of amoxycillin and clavulanate with granulates of amoxycillin.

35 As the absolute amount of drug substance increases, the tablet size also increases, making the tablets less attractive to swallow. Tablets further comprise excipients such as disintegrants, diluents, lubricants which are necessary to allow the tablet to be

manufactured and to enhance the pharmacokinetic performance of the tablets, once taken. Such excipients further add to the gross weight of a tablet. Furthermore, the conventional practice of formulating tablets comprising potassium clavulanate from a 1:1 blend of potassium clavulanate and a diluent, referred to above, further adds to the weight and size of a tablet. Thus, currently available (coated) tablets comprising 500/125 and 875/125 mg amoxycillin plus clavulanate (expressed as the weight of the corresponding free acids) have weights of 1050 and 1482mg, respectively, of which the drug substances account for about 70% and 81% respectively, by weight. Prototype formulations disclosed in earlier patent applications suggest 500/125mg tablets weighing 872mg (uncoated) (Example 1, GB 2 005 538-A), 950mg (uncoated), 1050mg (coated) (Example 14 & 15, WO 92/19227) and 875/125mg tablets weighing 1350mg (uncoated) and 1450mg (coated) (Example 14 & 15, WO 92/19227). There is therefore a need to provide tablet formulations having a smaller size for a given amount of drug substance.

A new co-amoxiclav dosage regimen of 1000/125 mg twice a day (bd) has generated a need for an appropriate tablet formulation(s). This unit dose has not so far been provided as a tablet formulation as merely increasing the size of the existing 875/125mg tablet was considered to give a tablet which would be unacceptably large for the patient to swallow.

Accordingly, in a first aspect, the present invention provides a pharmaceutical formulation comprising amoxycillin and clavulanate in a ratio of  $n:1$  where  $n$  is a number from 1 to 16 which comprises:

a first set of granulates comprising amoxycillin and clavulanate in a ratio from  $m:1$  to  $1:1$  where  $m$  is a number less than  $n$ ; and

a second set of granulates comprising amoxycillin and no clavulanate; in a ratio between the first and second sets of granulates to give an overall ratio between amoxycillin and clavulanate of  $n:1$ .

Preferably,  $n$  is 2, 4, 6, 7, 8, or 14.

Preferably,  $m$  is a number from 1 to 5, more preferably, 1, 2 or 4.

Preferably, the first set of granulates comprise amoxycillin and clavulanate in a ratio of  $1:1$ ,  $2:1$  or  $4:1$ , preferably  $2:1$ .

In a further aspect, the present invention provides for a range of pharmaceutical formulations comprising different ratios of amoxycillin and clavulanate from  $2:1$  to  $14:1$ ,

for instance selected from 2:1, 4:1, 6:1, 7:1, 8:1 and 14:1, which is prepared from a first set of granulates having a fixed ratio of amoxycillin and clavulanate, for instance 1:1 or 2:1, preferably 2:1, and a second set of granulates comprising amoxycillin, by combining different relative proportions of the two sets of granulates.

5

Thus, for instance, a range comprising formulations having ratios of 4:1, 7:1 and 8:1 may be prepared by combining granulates comprising amoxycillin and clavulanate in the ratio 2:1 with different relative amounts of granulates comprising amoxycillin, for instance in the ratios 3:2, 3:5 and 3:6 respectively.

10

The terms "amoxycillin" and "clavulanate" used herein, and unless otherwise specified, include both the free parent acids and derivatives such as salts thereof.

15

Weights and ratios are expressed in terms of the weight of parent compound amoxycillin or clavulanic acid, this terminology being used throughout this description unless otherwise stated.

20

Suitable derivatives of amoxycillin are amoxycillin trihydrate, anhydrous amoxycillin and alkali metal salts of amoxycillin such as sodium amoxycillin. Preferably, the equilibrium relative humidity (ERH) of the amoxycillin trihydrate used as a raw material for granulate production is carefully controlled by appropriate drying so that it does not compromise other aspects of the formulation. Preferably, the ERH is less than 50%, more preferably less than 30%, most preferably from 10 to 20%.

25

Suitable derivatives of clavulanic acid are alkali metal salts of clavulanic acid such as potassium clavulanate.

30

Preferably, formulations of this invention comprise amoxycillin trihydrate and potassium clavulanate, this combination having met with regulatory approval, and being particularly advantageous.

35

Suitable granulates for use in formulations of the present invention have been previously described in WO 92/19277 (SmithKline Beecham) and GB 2 005 538-A (Beecham Group). Suitable granulates may comprise in addition to amoxycillin and, if present, clavulanate, excipients conventionally used in such granulates, for instance an intra-granular disintegrant, intragranular lubricant and intragranular diluent.

Suitable intra-granular disintegrants include starches, such as maize starch and rice starch, crospovidone (cross-linked N-vinyl-2-pyrrolidinone; CLPVP), sodium starch glycollate, croscarmellose sodium and formaldehyde - casein, or combinations thereof. Preferred intra-granular disintegrants include sodium starch glycollate and CLPVP, in particular CLPVP, for example the product marketed under the trade names Polyplasdone XL and Polyplasdone XL-10. Preferably, the intragranular disintegrant is present in from 0.1 to 10%, preferably from 1.0 to 8.0%, more preferably from 1.25 to 3.5% by weight of the granulate.

- 10 Suitable intragranular lubricants are those conventional to the art, such as long-chain fatty acids, such as stearic acid, or salts thereof, in particular Group II metal salts, such as of magnesium or calcium. A preferred lubricant is magnesium stearate. Preferably, a lubricant is used in as low a proportion for instance from 0 to 1%, preferably from 0 to 0.5%, more preferably from 0 to 0.35%. Preferably, if the granulate is formed from ingredients which have been compacted using a roller compactor, it is possible to use no lubricant at all.

Preferably, when the granulate contains potassium clavulanate, granulates also include an intragranular diluent such as silica gel (which may also act as an intragranular dessicant), for instance the product Syloid AL-1, or microcrystalline cellulose (which may also act as a compression aid), for instance the product Avicel. Preferably, the intragranular diluent, if present, is silica gel on account of its superior dessicating power. Conventionally, a diluent is included in a weight ratio of about 1:1 with respect to the weight of potassium clavulanate, the granulate being prepared from a 1:1 blend of potassium clavulanate and silica gel or microcrystalline cellulose. It has however also been found possible to reduce the relative to amount of intragranular diluent, in particular silica gel, to a much lower level, and even avoid the use thereof. Accordingly, in a further aspect, the present invention provides for a granulate comprising amoxycillin and clavulanate as hereinbefore defined and an intragranular diluent present in from 0 to 100%, preferably from 0 to 50%, more preferably 5 to 25%, most preferably 5 to 15%, typically about 10% by weight of potassium clavulanate. Preferably, the dessicant diluent is included in a proportion of about 0.5-5% by weight of the amoxycillin plus clavulanate, more preferably from 1 to 3%. Such granulates allow the preparation of final formulations, in particular tablets, having a reduced overall weight and size.

Typically the proportion of amoxycillin and potassium clavulanate, if present, in a granulate is from 90 to 99.9wt %, preferably from 92 to 99wt %, for instance from 95 to

99wt %, such as 96.5 to 98.75% of the weight of the granulate. When the granulate contains a diluent, this may comprise up to 30wt % of the granulate, preferably, up to 25wt%, more preferably up to 10wt%, preferably up to 5wt%. When the granulate contains a diluent, the granulate will contain a correspondingly lower proportion  
5 amoxycillin or amoxycillin plus clavulanate, for example from 70 to 99.9wt % of the granulate, preferably from 85%, more preferably from 90%, typically from 93 to 97wt%.

Preferred amoxycillin granulates comprise from 95 to 99wt%, preferably from 96 to 98wt%, more preferably from 96.5 to 97.5wt% amoxycillin trihydrate and from 1 to  
10 5wt%, preferably 2 to 4wt%, more preferably from 2.5 to 3.5wt% of starch glycollate or CLPVP. Most preferred granulates consist essentially of about 97wt% amoxycillin trihydrate and 3wt% CLPVP.

Preferred amoxycillin and potassium clavulanate granulates comprise a 2:1 ratio of  
15 amoxycillin to clavulanate; silica gel present in from 5 to 15wt% of potassium clavulanate, typically about 10wt%; and CLPVP present in from 0.5 to 5wt% of amoxycillin trihydrate, preferably 1 to 4wt%, typically about 3%.

Preferably the particles of amoxycillin and clavulanate, if present, in the granulates are in  
20 the size range 1 $\mu$ m to 300 $\mu$ m, especially 10 $\mu$ m to 200 $\mu$ m. A typical suitable size distribution of the amoxycillin/clavulanic acid particles is : >200 $\mu$ , 5% or less; 200-100 $\mu$ , 5-15%; 100-50 $\mu$ , 7.5-15%; <50 $\mu$ , 70% or more.

Granulates according to the present invention may be presented in a variety of finished  
25 formulations, including, for instance, tablets, for example, swallow tablets, dispersible tablets and chewable, optionally effervescent, tablets; in capsules; aqueous syrups and sachets. These may be prepared by combining the granulates with additional, extragranular, excipients conventionally used in such formulations and further processing into finished formulations.

30 Tablets of the present invention may include an extra-granular disintegrant, for instance maize-starch and rice starch, CLPVP, sodium starch glycollate, croscarmellose sodium, microcrystalline or microfine cellulose, low-substituted hydroxypropylcellulose (i.e. cellulose partially substituted with 2-hydroxypropyl groups, e.g. less than 25% substituted,  
35 preferably 7-16% substituted), cross-linked sodium carboxymethylcellulose, swellable ion exchange resins, formaldehyde-casein, or alginates. A preferred extra-granular disintegrant is low-substituted hydroxypropylcellulose, for instance the product L-HPC

LH-11 (from Shinetsu). This also has useful binding properties, allowing the preparation of tablets with good hardness for a relatively lower proportion of ingredient. Other useful extra-granular disintegrants include CLPVP and sodium starch glycollate.

- 5 The proportion of extra-granular disintegrant to total tablet weight may vary between broad limits, for example 0.1-25 weight %. For example, low-substituted hydroxypropylcellulose, CLPVP or sodium starch glycollate may preferably be used in a proportion 0.1-15.0 weight %, preferably 1.0 - 10.0 weight %, preferably 3.0-8.0 weight % of the total tablet weight. If cellulose or a combination containing cellulose is used, e.g.  
10 as described above containing around 80-90% by weight of cellulose, the extra-granular disintegrant may comprise 1-20 weight %. Dispersible tablets will tend to comprise a relatively higher proportion of extra-granular disintegrant, to aid the dissolution process.

- 15 Tablets of the present invention may also include an extra-granular lubricant, for instance a long-chain fatty acid, such as stearic acid, or salts thereof, in particular Group II metal salt thereof, such as a magnesium or calcium salt, preferably magnesium stearate. Preferably, the extra-granular lubricant is used in from 0.1 to 2%, more preferably from 0.2 to 0.5, typically, 0.3 to 0.4 weight% of the tablet.

- 20 Formulations of the present invention may also include an extra-granular dessicant such as silica gel. This may be present in an amount up to 5% by weight of the formulation, preferably, up to 2% of a tablet formulation. Careful control of the Equilibrium Relative Humidity of the amoxycillin trihydrate used for the granulates allows the use of a relatively lesser proportion of an extra-granular dessicant.

- 25 Tablets may also include other conventional excipients, typically present up to about 10% of the total tablet weight, for instance flavoring agents, for example flavorings such as menthol, peppermint, vanilla or fruit flavorings, flavoring agents typically being present up to around 0.5-5% by weight of the whole tablet and sweeteners, e.g. aspartame, present of  
30 up to around 15mg per unit dose. Excipients may also include colouring agents, preservatives, suspending aids and fillers such as silicon dioxide, microcrystalline cellulose, dicalcium phosphate, lactose, sorbitol, calcium carbonate or magnesium carbonate. Such excipients are preferably mixed with the extra-granular disintegrant and lubricant (if present). The materials present in the tablets should have low free moisture content and  
35 preferably be pre-dried.



Tablets of the present invention may also contain an effervescent couple of known type, e.g. a solid acid and an alkali metal carbonate or bicarbonate which generates carbon dioxide on contact with water to assist in disintegration of the tablet, for instance monosodium citrate (56.04% w/w) and sodium bicarbonate (43.96% w/w). Preferably, the couple is provided as granules prepared from anhydrous powdered monosodium citrate and powdered sodium bicarbonate and compacted together by roller compaction, according to the process described in WO 97/02014 (SmithKline Beecham Laboratoires Pharmaceutiques).

- 10 The tablets may be film coated in a conventional manner, e.g. for cosmetic, palatability or production purposes. Suitable coatings include hydroxypropylcellulose, acrylate and/or methacrylate co-polymers such as the products available under the trade mark Eudragit, resins etc. Alternatively the coating may be an enteric coating, e.g. which is insoluble in acidic gastric juice but soluble in alkaline digestive juice. Such a coating enables the tablet to pass through the stomach into the duodenum, from where it is absorbed. Suitable enteric coatings include cellulose acetate phthalate.

- Preferably, a film coating is applied by aqueous film coating techniques, thereby avoiding the need for organic solvents. Suitable polymers for use in such techniques include hydroxypropylcellulose, hydroxypropylmethyl cellulose, ethylcellulose (for example ethylcellulose in a latex composition as supplied by the FMC Corporation as "Aqua-Coat" (trade mark)), methylhydroxyethylcellulose, polyvinylpyrrolidone ("PVP", e.g. as supplied under the name Povidone (trade mark), sodium carboxymethylcellulose and acrylate polymers (e.g. the known methacrylic acid esters supplied under the trade name "Eudragit" (trade mark)).

- A preferred polymer is hydroxypropylmethylcellulose ("HPMC") preferably in combination with a polyethylene glycol ("PEG"). PEG's of low molecular weight (200 to 600 series) are liquid at room temperature and find use as plasticisers. PEG's with high molecular weights (900 to 8000) are waxy solids at room temperature and are used in combination with low molecular weight PEG's and with other polymers such as HPMC to modify film properties and to contribute to tablet sheen.

- A preferred polymer which can be applied by aqueous film coating techniques is one or more hydroxypropylmethyl celluloses combined with one or more PEG's. HPMC polymers have the advantages of solubility in physiological fluids as well as water, non-interference with tablet disintegration, dissolubility or drug availability, formation of a

flexible film, freedom from objectionable taste or odour, stability to heat, light, air, moisture, compatibility to stabilisers, colourants opacifiers, and gloss. The hydroxypropylmethylcellulose functions as a film former, and the polyethylene glycol functions as a plasticiser. The hydroxypropylmethyl cellulose: polyethylene glycol ratio in the film coating is preferably between 7.5 : 1 to 5.5 : 1, e.g. around 6.5 : 1  $\pm$  10%. Preferably the hydroxypropylmethyl cellulose is applied in the form of a mixture of hydroxypropylmethyl cellulose 6 cps and 15 cps, in a ratio of around 2:1 to 4:1 e.g. around 3:1  $\pm$  10%. Preferably the polyethylene glycol is applied in the form of a mixture of polyethylene glycol 4000 and 6000 in a ratio between around 1:2 to 2:1, e.g. around 1:1. The film coat may also preferably include an opacifier, for example titanium dioxide (white). Preferably the opacifier may be present in around a 1:1  $\pm$  10% proportion with the hydroxypropylmethyl cellulose in the film coat.

The materials of the film coat are preferably applied by an aqueous film coating process, as application in this way form a film of a nature which also appears to contribute to the improved consistency in bioavailability. A suitable solids loading for the aqueous film coat is around 10-30% w/v, typically 10-20%, e.g. 15%  $\pm$  2%.

Preferably the film coating is applied so as to deposit a weight of dried film materials corresponding to between 0.5 and 5%, preferably 1 and 4%, more preferably 1.5 to 3.5% of the total coated tablet weight.

Preferably the proportion of amoxycillin and clavulanate in tablets of the present invention is 60-98% by weight of the total tablet (calculated as the weight of the particular form used, for instance the weight of amoxycillin trihydrate or potassium clavulanate).

Preferably, tablets according to the present invention are provided in convenient unit dosage forms, for instance comprising nominally 125/62.5, 250/62.5, 250/125, 500/62.5, 500/125, 875/125 and 1000/125mg amoxycillin/clavulanate. The tablets may be dispersed in water prior to ingestion, or may alternatively be chewed or swallowed whole.

The skilled man will readily appreciate that, in tablets of this invention, the granulates may be in a crushed state resulting from the compaction of the tablet, and consequently may not have discrete boundaries, or may be sub-divided or broken up into smaller granulates.

The invention is intended to include tablets having such a structure containing crushed granulates. Preferably the size of the granulates is in the range 100 $\mu$ m to 2mm, preferably around 1mm  $\pm$  0.25mm, maximum dimension.

Preferably the tablets are packaged in a container that inhibits the ingress of atmospheric moisture, e.g. blister packs or tightly closeable bottles etc. as conventional in the art. Preferably bottles also include a desiccant material to preserve the clavulanate.

5

By reducing the relative amount of excipients used, in particular intra-granular diluent, as well as minimising the amounts of extra-granular excipients used in a tablet formulation, tablets of reduced weight may be prepared. This is assisted by careful control of the moisture content of the various excipients, as well as amoxycillin trihydrate, to ensure that a larger dessicating capacity is not required. Accordingly, in a further aspect, the present invention provides for a tablet formulation comprising a first set of granulates comprising amoxycillin and clavulanate with a second set of granulates comprising amoxycillin and no clavulanate as hereinbefore defined in which the combined weight of all excipients is less than 20%, preferably less than 18%, more preferably less than 15%, typically from 10 to 12%, of the uncoated core weight of the tablet. This provides tablets which are easier for the patient to swallow. In addition, such reduced weight tablets cost less to produce as less raw materials are used, less material has to be transported around a manufacturing plant and the capacity of the equipment is effectively increased, since less material is processed per tablet.

20

Preferred reduced weight tablets comprise:

amoxycillin granulates which consist essentially of amoxycillin trihydrate present in about 97wt% and CLPVP present in about 3wt%;

amoxycillin and potassium clavulanate granulates which comprise a 2:1 ratio of amoxycillin to clavulanate; silica gel present in about 10wt% of potassium clavulanate and about 3wt% of CLPVP; and

extra granular excipients including:

silica gel (preferably 0.5 to 2.0%, more preferably about 1.0 to 1.2%); low-substituted hydroxypropylcellulose (preferably 3 to 8%, more preferably 5 to 6%); colloidal silica (preferably 0.1 to 0.5%, more preferably 0.1 to 0.3%); and magnesium stearate (preferably 0.2 to 0.5%, more preferably 0.3 to 0.4%); or

CLPVP (preferably 3 to 10%, more preferably 5 to 8%); and magnesium stearate (preferably 0.2 to 0.5%, more preferably 0.3 to 0.4%).

Preferred 500/62.5mg tablets will have tablet core weights in the range 700 to 800mg, more preferably 720 to 780mg. Preferred 500/125mg tablets will have tablet core weights in the range 800 to 950mg, more preferably 800 to 900mg, most preferably 800 to 850mg.

Preferred 875/125mg tablets will have tablet core weights in the range 1250 to 1375mg, more preferably 1250 to 1325mg. Preferred 1000/125mg tablets will have tablet core weights in the range 1400 to 1550mg, more preferably 1425 to 1475mg.

- 5 Especially preferred 500/125mg tablets will have a total weight (core plus coating) of less than 900mg, most preferably less than 850mg. Especially preferred 500/62.5mg tablets will have a total weight (core plus coating) of less than 850mg, most preferably less than 800mg. Especially preferred 875/125mg tablets will have a total weight (core plus coating) of less than 1400mg, most preferably less than 1350mg. Especially preferred  
10 1000/125mg tablets will have a total weight (core plus coating) of less than 1550mg, preferably less than 1500mg.

The skilled person will readily appreciate that the above mentioned tablets may also be produced by a more conventional approach, using a single set of granules comprising the  
15 amoxycillin and clavulanate in the final ratio of, for instance, 4:1, 7:1 or 8:1, rather than the two sets of granules hereinbefore described, using intra- and extra-granular excipients in the same proportions. The present invention covers all such tablets.

- As hereinbefore described, a 1000/125mg unit dosage in a tablet formulation may be  
20 provided as a single, preferably reduced weight, tablet. Preferred reduced weight 1000/125mg tablets comprise amoxycillin and clavulanate present in from 83 to 95%, preferably 85 to 93%, more preferably, 87 to 91% of the core tablet weight and pharmaceutically acceptable excipients present in from 5 to 17%, preferably 7 to 15%,  
25 more preferably, 9 to 13% by weight of the core weight of the tablet (excluding any coating). The skilled person will however readily appreciate that the dosage may also be provided using two 500/62.5mg tablets (ratio amox/clav = 8:1). Such tablets will be intrinsically smaller as they contain less drug substance so such tablets may also be based on more conventional formulations, for instance existing 500/125mg formulations where there is not such a need to reduce the weight and size of the tablet. Accordingly, in a  
30 further aspect, the present invention provides for a tablet comprising about 500mg amoxycillin and about 62.5mg potassium clavulanate and pharmaceutically acceptable excipients. The skilled person will further appreciate that a 1000/125mg dosage may also be provided by the combination of a 500/125mg amoxycillin/clavulanate tablet and a 500mg amoxycillin tablet, for instance using existing such tablets or adapting one or the  
35 other to more readily distinguish between the two, for instance by shape or colour. Patient compliance with such two tablet strategies may be enhanced by providing the tablets in a

blister pack presentation, with each blister containing two tablets. The present invention covers all such approaches.

5 A 1000/125mg unit dosage may also be provided as a chewable, optionally effervescent tablet, whereby the problem of having to swallow whole a large tablet is overcome by the patient chewing the tablet and breaking it down into smaller pieces prior to swallowing. Accordingly, in a further aspect, the present invention provides a chewable, optionally effervescent, tablet comprising 1000/125mg amoxycillin and clavulanate.

10 Chewable tablets may be prepared by combining granulates as hereinbefore described with extra-granular excipients conventionally used to form a chewable base, for instance, mannitol, sorbitol, dextrose, fructose, or lactose, alone or in combination, preferably present in from 10 to 30% based on the weight of the final tablet, more preferably from 15 to 25%. The tablets may also contain conventional lubricants such as magnesium stearate,  
15 sweetening agents such as aspartame or sodium saccharin and flavouring and colouring agents. A disintegrating agent may also be incorporated as an extragranular excipient, to give the patient the option of dispersing the tablet in a small amount of water prior to administration. Suitable disintegrating agents include cellulose-based products such microfine cellulose, microcrystalline cellulose or hydroxypropyl cellulose as well as sodium  
20 strach glycollate and CLPVP. The disintegrant is preferably present in from 5 to 30%, more preferably from 5 to 15%, based on the weight of the final tablet.

Preferably, the chewable tablet is also provided with an effervescent couple. Effervescent  
25 chewable tablet formulations comprising 250/125 or 250/62.5mg amoxycillin/clavulanate have previously been described in EP 0 396 335 A1 (Beecham Group plc). Suitable such effervescent couples are well known in the art and typically comprise comprise a solid acid and an alkali metal carbonate or bicarbonate which generates carbon dioxide on contact with water, for instance citric acid, monosodium citrate or sodium hydrogen citrate and sodium (bi)carbonate. Other pharmaceutically acceptable acid/alkaline or alkaline earth  
30 metal carbonate mixtures may also be used, for instance tartaric, adipic, fumaric or malic acids and sodium, potassium or calcium (bi)carbonates or sodium glycine carbonate. Preferably, the two components are employed in a chemical molecular equivalent basis in the range 4:3 to 1:3, more preferably about 2:3 (acidic:basic component).

35 Preferred couples comprises citric acid/sodium bicarbonate and monosodium citrate/sodium bicarbonate, in particular monosodium citrate (56.04% w/w) and sodium bicarbonate(43.96% w/w). Preferably, this is provided as granules prepared from anhydrous powdered monosodium citrate and powdered sodium bicarbonate and

compacted together by roller compaction, according to the process described in WO 97/02014 (SmithKline Beecham Laboratoires Pharmaceutiques). Suitable grades of anhydrous powdered monosodium citrate comprise particles which are substantially (i.e. about more than 90%) within the range 0 to 500 microns, preferably 355 microns, more preferably 0 to 250 microns. Suitable grades are available from Roche (monosodium citrate anhydrous powder, maximum of 5%w/w with grain size >0.250mm), Boehringer Ingelheim (monosodium citrate wasserfrei Art-Nr 661 511, minimum of 90%w/w with grain size < 0.150mm), Jungbunzlauer (maximum of 5%w/w with grain size >0.355mm) and Haarmann & Reimer Corp. (maximum of 1% with grain size >0.500mm). Suitable grades of powdered sodium bicarbonate comprise particles which are substantially (i.e. about more than 90%) within the range of 0 to 500 microns, preferably 270 microns, more preferably 0 to 130 microns. Suitable grades of powdered sodium bicarbonate are available from Solvay, for instance the grades 0 to 13 (particle size, by sieving method: >0.16mm max; 15g/kg) and extra-fine (particle size by sieving method: >0.125mm max; 20g/kg).

Preferably, the couple is present in from 5 to 30% of the final tablet weight, more preferably, from 5 to 15%, typically about 10%.

The granulates hereinbefore described may also be used for preparing other pharmaceutical formulations, in addition to tablets. For instance, they may be supplied as a sachet product containing a free-flowing granulated formulation in a suitable unit dose, for reconstituting in water to form an syrup formulation immediately prior to use, for example for administration to small children. Such free-flowing granulated formulation may comprise further excipients such as sweetening agents, thickeners, preservatives such as sodium benzoate and buffers such as sodium citrate.

Preferred sachets comprise:

amoxycillin granulates which consist essentially of amoxycillin trihydrate present in about 97wt% and CLPVP present in about 3wt%;  
amoxycillin and potassium clavulanate granulates which comprise a 2:1 ratio of amoxycillin to clavulanate; silica gel present in about 10wt% of potassium clavulanate and CLPVP present in about 3wt% of amoxycillin trihydrate; and  
extra granular excipients including silica gel (preferably 5 to 20%, more preferably about 10 to 15%), and flavour (preferably 2 to 10%, more preferably 3 to 8%).

Such sachets may preferably be provided as 'sugar-free' formulations, comprising, as an artificial sweetening agent such as aspartame, rather than sugar. Preferably, such formulations comprise preferably 1 to 10%, more preferably about 1 to 5% aspartame.

- 5 Such sachet formulations are of reduced weight in comparison to existing sachet formulations comprising corresponding weights of amoxycillin and clavulanate and therefore may be provided in smaller sachets, saving on packaging costs.

- 10 Further suitable formulations include encapsulated formulations which may optionally include an extra-granular lubricant, which if present is preferably in an amount of less than 0.5% by weight of the granulates, being contained within a pharmaceutical capsule. The pharmaceutical capsule may be an entirely conventional capsule, capable of dissolving in the stomach to release its contents, for example made of gelatine.

- 15 The sachet and encapsulated formulations described above preferably contain unit doses of amoxycillin, for instance sachets comprising nominally 125/31.25, 250/31.25, 250/62.5, 500/125, 500/62.5, 875/125 or 1000/125mg of amoxycillin/clavulanate.

- 20 Other suitable formulations include formulations for paediatric use which are reconstituted into aqueous suspensions prior to use. Such formulations may comprise further extragranular excipients such as, for example, a dessicating agent, for instance silica gel or dried maltodextrin, thickeners such as xanthan gum, carboxymethylcellulose sodium, silica gel, and hydroxypropylmethyl cellulose, preservatives such as sodium benzoate, sweetening agents such as aspartame, acesulfamate potassium, and sodium saccharin, 25 lubricants such as magnesium stearate, glidants such as colloidal silicon dioxide, and flavouring agents such as fruit flavour(s). Such formulations are found to be less powdery and so do not coat the inside of the bottle containing them, thereby enhancing their aesthetic attributes. Further more, preferred formulations have a lower bulk so can be provided in a smaller container. Formulations are provided comprising an appropriate 30 quantity of amoxycillin and clavulanate to be reconstituted into aqueous solution, for instance 100/12.5mg/ml in 30ml, 100/12.5mg/ml in 60ml, 125/31.25mg/5ml in 60 to 80ml and 250/62.5mg/5ml in 60 to 80ml.

- 35 The skilled person will readily appreciate that the aforementioned sachet, encapsulated and paediatric formulations may also be produced by a more conventional approach, using a single set of granules comprising the amoxycillin and clavulanate in the final ratio of, for instance, 4:1, 7:1 or 8:1, rather than the two sets of granules hereinbefore described, using

intra- and extra-granular excipients in the same proportions. The present invention covers all such formulations.

5 In a further aspect, the present invention provides for pharmaceutical formulations comprising amoxycillin and clavulanate in a ratio of n:1, as hereinbefore defined, preferably 2:1, 4:1, 7:1 and 8:1, and which comprise granulates consisting essentially of amoxycillin and clavulanate, CLPVP (as an intragranular disintegrant) present in from 0.5 to 5wt% of amoxycillin trihydrate, preferably 1 to 4wt%, typically about 3% and silica gel (as an intragranular diluent/dessicant) present in from 5 to 15wt% of potassium  
10 clavulanate, typically about 10wt%.

In a further aspect, the present invention provides a process for preparing the formulations of the present invention hereinbefore defined which process comprises blending together a first set of granulates comprising amoxycillin and clavulanate with a second set of  
15 granulates comprising amoxycillin and no clavulanate in an appropriate ratio and then further processing to obtain the final desired formulation, for instance, compressing into tablets, filling into sachets, bottles or capsules.

20 It will be readily appreciated that a range of different formulations with differing ratios of amoxycillin to clavulanate may be readily be prepared by utilising as a common intermediate granulates comprising a given ratio of amoxycillin and clavulanate, for instance 2:1, and then adding in differing relative amounts of granulates comprising amoxycillin alone, to provide the different final ratios.

25 It will be further appreciated that the use of granulates comprising silica gel and silica gel as an extra-granular excipient, rather than microfine cellulose allows the development of a range of diverse formulation types with fewer different types of excipients, thereby further reducing the complexity of the manufacturing process.

30 Preferably, the amoxycillin and clavulanate, if present, (drug substance) is milled and sieved to achieve the desired particle size range. Preferably, the intra-granular disintegrant is also milled and sieved to a suitable particle size, for example, in the case of CLPVP, about 30 $\mu$ , but particle size does not appear to be critical. Prepared drug substance and intra-granular excipients are then blended together in a dry state, and compacted under  
35 pressure. This may be by conventional dry compaction means, for example pressing, rolling, slugging extrusion etc, and a suitable pressure for the compaction process is 30-200KN, for instance 70-100, preferably, 80-90kN for amoxycillin granulates and 50-80,



preferably, 60-70kN for amoxycillin/clavulanate granulates. The above-described granulate formulations are particularly suited to formation by roller compaction. The use of roller compaction to prepare granules comprising amoxycillin and potassium clavulanate is described in WO 92/19227 and WO 95/28927 (both to SmithKline Beecham).

5

Potassium clavulanate is known to be highly sensitive to moisture so that it is preferred that the preparation of the formulations of the invention is carried out under conditions of low humidity, for instance less than 30% RH, more preferably less than 20% RH, ideally 7-10% RH.

10

For further processing into tablets, it may be necessary to mill and sieve the granulates so as to achieve a suitable size fraction of the granulate. Compression into tablets may be carried out in a conventional manner, for instance on a conventional tableting machine. As an optional further step the tablets may be coated as described above.

15

Formulations of this invention may be provided for treatment of bacterial infections generally, for example one or more of *inter alia* upper respiratory tract infections, lower respiratory tract infections, genito- urinary tract infections and skin and soft tissue infections.

20

Accordingly, in a further aspect, the present invention provides for the use of a first set of granulates comprising amoxycillin and clavulanate with a second set of granulates comprising amoxycillin and no clavulanate in the manufacture of a medicament for treating bacterial infections.

25

The invention will now be described, by way of example only. In these, the weights and % are the actual weights and % of amoxycillin trihydrate and potassium clavulanate, rather than the corresponding free acid equivalents.

In the following examples it is preferred to use amoxycillin trihydrate in which the Equilibrium Relative Humidity is in the range 10-20%, thereby allowing the relative amount of dessicant to be reduced to a minimum level.

5 **Example 1 - Amoxycillin granulate**

Amoxycillin trihydrate was milled and sieved using an 0.04 or 0.027 inch (1.0 - 0.7 mm) aperture sieve, and was mixed for 15 minutes in a blender with dried cross-linked polyvinylpyrrolidinone (CLPVP) having a molecular weight of approximately 1 million and a density of 1.22 mg/cm<sup>3</sup> (Polyplasdone XL - Trade Mark), the mixture containing 3.4% of CLPVP by weight. The mixture was consolidated using a roller compactor at a controlled pressure of 50KN. The compacted flakes were granulated in a mill, or granulated through a sieve fitted with a 1mm mesh to obtain a suitable size fraction.

**Example 2 - Amoxycillin granulate**

15	Amoxycillin trihydrate	97.087 %
	CLPVP (Polyplasdone XL)	2.913

20 Milled amoxycillin trihydrate and crospovidone (moisture <2%, sieved on a 1mm sieve) were separately weighed out and then introduced into a blender (amox first) for blending together, both operations being carried out in a controlled area (t° = 20 +/- 1°C, RH<30%). The resultant blend was discharged into double polyethylene bags in labelled containers and stored for subsequent roller compaction.

25 A Bepex roller compactor was fed with blend, maintaining a constant level in the feeding hopper, with the load cell set at 15kN and the compactor at a roller strength of 80-90kN. The resultant flakes were calibrated on oscillating granulator fitted with 1mm aperture screen. Uncompacted material which passed through a 1mm sieve was recycled. The granules were weighed and collected in double polyethylene bags and kegs. The roller compaction and calibration was performed in a controlled area (t° = 20 +/- 1°C, RH<30%)

30 **Example 3 - Amoxycillin granulate**

Granulates were prepared using a procedure identical to that of example 1, comprising 97.12 weight % amoxycillin trihydrate together with 2.88 weight % sodium starch glycollate (as "Primogel") as intra-granular disintegrant.

35 **Example 4 - Amoxycillin/clavulanate granulate**

Granulates comprising amoxycillin and clavulanate in a ratio of 2:1 were prepared using a procedure identical to example 1, comprising:

Amoxicillin trihydrate	46.3%
Potassium clavulanate	24.3
Silica gel (Syloid AL-1)	24.3
CLPVP (Polypladsone XL) (dried)	1.38

5

Potassium clavulanate and silica gel are used as a 1:1 blend (based on the actual weight of potassium clavulanate).

#### Example 5 - Amoxicillin/clavulanate granulate

- 10 Granulates comprising amoxicillin and clavulanate in a ratio of 2:1 and a lesser proportion of silica gel than in Example 4 were prepared using a procedure identical to example 1, comprising:

Amoxicillin trihydrate	63.3%
15 Potassium clavulanate	31.7
Silica gel (Syloid AL-1)	3.1
CLPVP (Polypladsone XL) (dried)	1.9

- 20 Milled amoxicillin, crospovidone (moisture <2%) and silica gel (sieved on 1 mm) and finally a 1:1 blend of amoxicillin trihydrate/potassium clavulanate (sieved on 1 mm) were introduced in succession into a blender and blended together in a controlled area ( $t^{\circ} = 20 \pm 1^{\circ}\text{C}$ ,  $\text{RH} < 30\%$ ). The blend was then discharged into double polyethylene bags with desiccant in labelled containers for storage before roller compaction.
- 25 A Bepex roller compactor was fed with blend maintaining a constant level in the feeding hopper, with the load cell set at 15kN; and the compactor at a roller strength of 60-70kN. The resultant flakes were calibrated on oscillating granulator fitted with 1mm aperture screen. Uncompacted material which passed through a 1mm sieve was recycled. The granules were weighed and collected in double polyethylene bags and kegs. The roller
- 30 compaction and calibration was performed in a controlled area ( $t^{\circ} = 20 \pm 1^{\circ}\text{C}$ ,  $\text{RH} < 30\%$ )

#### Example 6 - Reduced weight tablets

- 35 A reduced weight tablet comprising 500mg/62.5mg, 500mg/125mg, 875mg/125mg or 1g/125mg amoxicillin/clavulanate was prepared by combining granulates comprising amoxicillin and potassium clavulanate (Example 5) in a 2:1 ratio with granulates comprising amoxicillin (Example 2), to give an overall ratio of 8:1, 4:1, 7:1 or 8:1 respectively with extragranular excipients, in particular low substituted hydroxypropyl cellulose as the extragranular disintegrant, so that the overall composition was as follows:
- 40

	500/125	875/125	1g/125
	mg	mg	mg
<b>Core</b>	mg	mg	mg
Amoxycillin trihydrate (100% of theory; equivalent to 500, 875mg or 1g Amox. 100%)	573.87	1004.272	1147.74
Potassium Clavulanate (100% of theory; equivalent to 125mg Clavulanic acid 100%)	148.93	148.930	148.930
Silica Gel <sup>1</sup> (intra-granular)	14.89	14.890	14.890
CLPVP (intra-granular)	17.21	30.130	34.430
Silica Gel <sup>1</sup> (extra-granular)	8.3	14.000	16.000
Low substituted hydroxypropyl cellulose <sup>2</sup>	50.00	70.000	80.000
Colloidal silica <sup>3</sup>	1.70	2.700	3.000
Magnesium stearate	3.00	4.600	5.300
Total weight (core)	817.9	1289.520	1450.29
<b>Coating</b>			
Hydroxypropyl methylcellulose 5cP	6.93	10.925	12.288
Hydroxypropyl methylcellulose 15cP	2.31	3.642	4.096
Polyethylene Glycol 4000	1.369	2.158	2.427
Polyethylene Glycol 6000	1.369	2.158	2.427
Titanium dioxide	9.022	14.225	15.997
Total weight of coating	21	33.108	37.235
Total weight of coated tablet	838.9	1322.628	1487.525
	500/62.5	500/62.5	500/62.5
	mg	mg	mg
<b>Core</b>	mg	mg	mg
Amoxycillin trihydrate (100% of theory; equivalent to 500, 875mg or 1g Amox. 100%)	573.87	573.87	573.87
Potassium Clavulanate (100% of theory; equivalent to 125mg Clavulanic acid 100%)	74.46	74.46	74.46
Silica Gel <sup>1</sup> (intra-granular)	7.45	7.45	7.45
CLPVP (intra-granular)	17.21	17.21	17.21
Silica Gel <sup>1</sup> (extra-granular)	7.4	15.3	17.2
Low substituted hydroxypropyl cellulose <sup>2</sup>	44.5	61.3	78.4
Colloidal silica <sup>3</sup>	1.50	1.50	1.50
Magnesium stearate	2.7	2.8	2.8
Total weight (core)	729.09	753.89	772.99
Coating (as above)	19	19	19
Total weight of coated tablet	748.09	772.89	792.99

- 1 Syloid AL-1
- 2: L-HPC LH-11 or equivalent;
- 3: Aerosil 200 or equivalent.

5

The manufacture of tablets was carried out in a controlled area ( $t^{\circ} = 20 \pm 1^{\circ}\text{C}$ ,  $\text{RH} < 30\%$ ). A compression mix was prepared by introducing into a blender Amoxycillin granulates; Amoxycillin/Clavulanate 2/1 granulates; silica gel, L-HPC LH-11 and colloidal silicon dioxide sieved on 0.5mm. These materials were blended together. Magnesium stearate (sieved on 0.5mm) was then added, followed by further blending. This mix was then compressed using concave oval punches to give tablets of the desired weight. Uncoated tablets were sampled every 5-15 mn during compression run and checked for hardness, thickness, mean weight, uniformity of mass and friability.

10

- 15 The uncoated tablet cores were then film coated with a coating suspension (15w/w% in water) on a suitable coating machine, rotating the cores and spraying the film coating suspension until theoretical quantity of film coat had been applied (WO 95/28927, SmithKline Beecham).

- 20 The film coated tablets were then stored in appropriate sealed containers.

For the 500/125mg tablet, the tablet has a total weight of about 817.9mg, including 63mg of extragranular excipients plus a coating of about 21mg. Amoxycillin trihydrate and potassium clavulanate account for about 89.6% of the core weight of the tablet. This may be contrasted with the present 500/125mg tablet which has a core weight of 1050mg of which amoxycillin trihydrate and potassium clavulanate account for about 69.3% and microcrystalline cellulose about 27%. The quantities may be halved to give a 250/62.5mg tablet

25

- 30 In the 875/125 mg, amoxycillin trihydrate and potassium clavulanate account for about 89.43% of the core weight of the tablet. This can be contrasted with the current 875/125mg tablet which has a core weight of 1450mg, of which amoxycillin trihydrate and potassium clavulanate account for about 80% and microcrystalline cellulose about 15.6% (WO 95/28927, SmithKline Beecham).

35

In the 1g/125mg tablets, amoxycillin trihydrate and potassium clavulanate account for about 89.41% of the core weight of the tablet. The quantities may be halved, to give a 500/62.5mg tablet.

- 40 **Example 7 - Reduced weight tablets**

- A reduced weight tablet comprising 500mg/125mg, 875mg/125mg or 1g/125mg amoxycillin/clavulanate was prepared by combining granulates comprising amoxycillin and potassium clavulanate (Example 5) in a 2:1 ratio with granulates comprising amoxycillin (Example 1), to give an overall ratio of 4:1, 7:1 or 8:1 respectively with extragranular excipients, in particular CLPVP as the extragranular disintegrant, so that the overall composition was as follows:

	500/125 mg	875/125 mg	1g/125 mg
<b>Core</b>			
Amoxycillin trihydrate (based on 86.4% assay for amox; equivalent to 500, 875mg or 1g Amox. 100%)	578.7	1012.7	1157.4
Potassium Clavulanate (based on 82.5% assay for KCA; equivalent to 125mg Clavulanic acid 100%)	151.5	151.5	151.5
Silica Gel <sup>1</sup> (intra-granular)	15.2	15.2	15.2
CLPVP (intra-granular)	17.4	30.4	34.7
CLPVP (extra-granular)	60	90	100
Magnesium stearate	3.00	4.50	5.0
Total weight (core)	825.8	1304.3	1463.8

<sup>1</sup> Syloid AL-1

- 10 A suitable solvent based coating coating for the cores of the above tablets is as follows:

Dimethicone 200	0.04mg
Ethyl cellulose	3.21
Hydroxypropylmethyl cellulose 15cps	12.8
Titanium dioxide suspension	11.34
Diethyl phthalate	3.78
Total weight of coating	31.17

#### Example 8 - 500mg/125mg and 1g/125mg Sachets

- 15 Granulates are prepared using procedures identical to Examples 1 and 5. The granulates are then blended in the appropriate ratio with typical sachet excipients to produce a sachet formula comprising:

	500/125 mg	1g/125mg
Amoxycillin trihydrate 100% of theory	573.87 mg	1147.4

(equivalent to 500mg or 1g amoxicillin 100%)

Potassium Clavulanate 100% of theory (equivalent to 125mg Clavulanic acid 100%)	148.93	148.93
CLPVP (intra-granular)	17.21	34.42
Silica gel <sup>1</sup> (intra-granular)	14.89	14.89
Silica gel <sup>1</sup> (extra-granular)	65.00	130.00
Aspartame	15.00	30.00
Peach-Lemon-Strawberry flavour	30.00	60.0

Total Weight	864.90	1565.98
--------------	--------	---------

<sup>1</sup> Syloid AL-1

Sachets comprising 500/62.5mg and 250.31.25mg may be prepared using *pro rata* amounts based on the 1g/125mg formulation.

5

#### Example 9 - 250/62.5, 500/125 and 875/125mg Sachets

Granulates are prepared using procedures identical to Examples 1 and 5. The granulates are then blended in the appropriate ratio with typical sachet excipients to produce a sachet formula comprising:

10

	250/62.5 mg	500/125 mg	875/125 mg
Amoxicillin trihydrate (based on 86.4% assay for amox, equivalent to 250, 500 and 875 mg amoxicillin 100%)	289.35	573.87 mg	1147.4
Potassium Clavulanate (based on 82.5% assay for K clav, equivalent to 62.5 and 125mg Clavulanic acid 100%)	75.75	148.93	148.93
CLPVP (intra-granular)	8.7	17.4	30.4
Silica gel <sup>1</sup> (intra-granular)	7.6	15.2	15.2
Silica gel <sup>1</sup> (extra-granular)	167.5	335	335
Aspartame	6	12.00	12.00
Peach-Lemon-Strawberry flavour	107	214	214
Microcrystalline cellulose	213.1	426.2	229.2

<sup>1</sup> Syloid AL-1

#### 15 Example 10 - 100mg/12.5mg/ml suspension - 30ml

Granulates are prepared using procedures identical to Examples 1 and 5. The granulates are then blended in the appropriate ratio with typical suspension excipients to produce a sachet formula comprising:

5	Amoxycillin trihydrate 100% of theory (equivalent to 3000mg Amoxycillin 100%)	3443.22 mg
	Potassium Clavulanate 100% of theory (equivalent to 375mg Clavulanic acid 100%)	446.79
	CLPVP (intra-granular)	103.29
10	Silica gel <sup>1</sup> (intra-granular)	44.68
	Silica gel <sup>1</sup> (extra-granular)	500.00
	Xanthan gum	25.20
	Carboxymethylcellulose sodium salt	250.00
	Sodium benzoate	51.00
15	Hydrophobic colloidal silica	15.00
	Aspartame	96.00
	Magnesium stearate	10.00
	Strawberry flavour	150.00
20	Total weight	<u>5135.50 mg</u>

<sup>1</sup> Syloid AL-1

The formulation is made up into 30ml of aqueous solution immediately prior to first use.

25 The same formulation may also be made up into 60ml aqueous solution.

#### Example 11 - Chewable effervescent tablet (1g/125mg)

	mg
Amoxycillin trihydrate (equivalent to amoxycillin 1000.0)	1147.74
Potassium clavulanate (equivalent to clavulanic acid 125.0)	148.93
CLPVP	34.43
Silica gel <sup>1</sup> (intragranular)	14.89
Silica gel <sup>1</sup> (extragranular)	120.00
Monosodium citrate	156.91
Sodium bicarbonate	123.09
Microcrystalline cellulose <sup>2</sup>	280.00
Flavour	90.00
Aspartame	40.00
Magnesium stearate	30.00
Mannitol DC	614.01



---

Total weight	2,800
--------------	-------

---

<sup>1</sup> Crospovidone

<sup>2</sup> Syloid AL-1

<sup>3</sup> Avicel PH112

5

**Example 12 - Conventional 500/125mg tablet**

**Core**

Amoxicillin trihydrate	578.87
(equivalent to amoxicillin 500.0)	
Potassium clavulanate	148.93
(equivalent to clavulanic acid 125.0)	
Anhydrous colloidal silica	10.50
Sodium starch glycollate <sup>1</sup>	21.00
Magnesium stearate	7.27
Microcrystalline cellulose	qs 1050

**Coating**

Methylhydroxypropylcellulose	11.88
Polyethylene glycol 4000	1.76
Polyethylene glycol 6000	1.76
Titanium dioxide	11.60
Dimethicone	0.14
Coating	27.14

---

Total	1077mg
-------	--------

---

<sup>1</sup> (Primojel/Explotab)

10

**Example 13 - 500/125mg tablet**

**Core**

Amoxicillin trihydrate	581.4
(equivalent to amoxicillin 500.0, based on 86% potency)	
Potassium clavulanate	76.2

(equivalent to clavulanic acid 62.5, based on 82% potency)

Colloidal silicon dioxide	8.2
Sodium starch glycollate	16.4
Microcrystalline cellulose	129.1
Magnesium stearate	5.7
Weight	817.0

**Coating**

as in Example 6 24.5

Total	841.5mg
-------	---------

Amoxicillin, clavulanate source (either as a 1:1 blend of clav:amox or a 1:1 blend of clav and microcrystalline cellulose), most of the microcrystalline cellulose and a portion of the magnesium stearate were blended together. This blend was then roller-compacted and milled to form granules. These granules were blended with the sodium starch glycollate, colloidal silicon dioxide, the remaining microcrystalline cellulose (approx 38.55 of the total amount) and the magnesium stearate, and the blend then compressed into tablet cores. In a final step, the cores were coated with an aqueous suspension of the coating.

The weights and relative proportions of the components of the foregoing examples 1 to 13 may be varied about the figures listed but preferably are within  $\pm 10\%$ , more preferably within  $\pm 5\%$ , preferably within  $\pm 2.5\%$ . Overages of active ingredients may be used if necessary and justified.

It will be appreciated that the foregoing formulations may also be produced using a single set of granules comprising amoxicillin and clavulanate in the final ratio of 4:1, 7:1, or 8:1 rather than the two sets described, using intra- and extra-granular excipients in the same proportions. The present invention covers all such formulations.

## Claims

1. A pharmaceutical formulation comprising amoxycillin and clavulanate in a ratio of  $n:1$  where  $n$  is a number from 1 to 16 which comprises:
  - 5 a first set of granulates comprising amoxycillin and clavulanate in a ratio from  $m:1$  to  $1:1$  where  $m$  is a number less than  $n$ ; and
  - a second set of granulates comprising amoxycillin and no clavulanate;in a ratio between the first and second sets of granulates to give an overall ratio between amoxycillin and clavulanate of  $n:1$ .
- 10 2. A formulation as claimed in claim 1 in which first set of granulates comprise amoxycillin and clavulanate in a ratio  $1:1$  or  $2:1$ .
3. A formulation as claimed in claim 1 or 2 in which  $n$  is 2, 4, 6, 7, 8 or 14.
- 15 4. A formulation as claimed in any one of claims 1 to 3 in which amoxycillin is present as amoxycillin trihydrate.
5. A formulation as claimed in any one of claims 1 to 4 in which clavulanate is present as potassium clavulanate.
- 20 6. A formulation as claimed in any one of claims 1 to 5 in which the granulates comprises an intragranular disintegrant.
- 25 7. A formulation as claimed in any one of claims 1 to 6 in which the first set of granulates consist essentially of amoxycillin, potassium clavulanate, silica gel and an intragranular disintegrant.
8. A formulation as claimed in any one of claims 1 to 6 in which the second set of granulates consist essentially of amoxycillin and an intragranular disintegrant.
- 30 9. A formulation as claimed in any one of claims 6 to 8 in which the intragranular disintegrant is cross-linked N-vinyl-2-pyrrolidone or sodium starch glycollate.
- 35 10. A formulation as claimed in any one of claims 1 to 9 further comprising an extra-granular excipient which is low-substituted hydroxypropylcellulose.

11. A formulation as claimed in any one of the preceding claims in the form of a tablet, sachet, capsule or a powder for reconstitution as an aqueous syrup.
12. A tablet formulation comprising a first set of granulates comprising amoxycillin and clavulanate with a second set of granulates comprising amoxycillin and no clavulanate as defined in claim 1 in which the combined weight of all excipients is less than 20% of the uncoated core weight of the tablet.
13. A tablet formulation as claimed in claim 12 which comprises:
- 10 amoxycillin granulates which consist essentially of amoxycillin trihydrate present in about 97wt% and CLPVP present in about 3wt%;
- amoxycillin and potassium clavulanate granulates which comprise a 2:1 ratio of amoxycillin to clavulanate; silica gel present in about 10wt% of potassium clavulanate and about 3wt% of CLPVP; and
- 15 extra granular excipients including silica gel; low-substituted hydroxypropylcellulose or CLPVP; colloidal silica and magnesium stearate
14. A tablet formulation as claimed in claim 13 in which the tablet cores have the weights:
- 20 500/62.5 - 700-800mg;
- 500/125mg - 800 to 950mg;
- 875/125mg - 1250 to 1350mg; and
- 1000/125mg - 1400 to 1550mg.
15. Amoxycillin/clavulanate tablets having a total tablet weight (core plus coating):
- 25 500/62.5mg - less than 850mg;
- 500/125mg - less than 900mg;
- 875/125mg - less than 1400mg; and
- 1000/125mg - less than 1550mg.
16. A 1000/125mg comprising amoxycillin and clavulanate tablet present in from 83 to 95% and pharmaceutically acceptable excipients present in from 5 to 17%, by weight of the core weight of the tablet (excluding any coating).
17. A tablet comprising about 500mg amoxycillin and about 62.5mg potassium clavulanate and pharmaceutically acceptable excipients.
18. A tablet blister pack comprising in each blister two of the tablets defined in claim 17.

19. The use of two tablets defined in claim 17 to provide a unit dosage of 1000mg amoxycillin and 125mg potassium clavulanate.
- 5 20. A tablet formulation which is a chewable, optionally effervescent, tablet and which comprises about 1000mg amoxycillin and about 125mg clavulanate.
21. A chewable effervescent tablet as claimed in claim 20 in which the effervescent couple is monosodium citrate and sodium bicarbonate, preferably provided as granulates.
- 10 22. A process for preparing a formulation according to any one of the preceding claims which comprises blending together a first set of granulates comprising amoxycillin and clavulanate with a second set of granulates comprising amoxycillin and no clavulanate in an appropriate ratio with other excipients and then, if necessary and desired, further
- 15 processing the blend to obtain the final desired formulation.
23. A process as claimed in claim 22 which comprises the preliminary step of preparing the first and/or second set of granulates by roller compaction.
- 20 24. The use of a first set of granulates comprising amoxycillin and clavulanate in the ratio 2:1 and a second set of granulates comprising amoxycillin and no clavulanate, in the manufacture of a pharmaceutical formulation comprising amoxycillin and clavulanate in a ratio of greater than 2:1.
- 25 25. The use of a first set of granulates comprising amoxycillin and clavulanate with a second set of granulates comprising amoxycillin and no clavulanate, in the manufacture of a medicament for treating bacterial infections.
- 30 26. A granulate as defined in any one of the preceding claims comprising amoxycillin and clavulanate plus an intragranular diluent present in a ratio of from 1:1 to 1:20 by weight of the clavulanate.
- 35 27. A range of pharmaceutical formulations comprising different ratios of amoxycillin and clavulanate from 2:1 to 14:1, for instance selected from 2:1, 4:1, 6:1, 7:1, 8:1 and 14:1, which is prepared from a first set of granulates having a fixed ratio of amoxycillin and clavulanate, for instance 1:1 or 2:1, preferably 2:1, and a second set of granulates

comprising amoxycillin, by combining different relative proportions of the two sets of granulates.

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 98/00811

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/43 A61K9/50 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y, L  Y	WO 95 20946 A (SMITHKLINE BEECHAM PLC ;EBBERS WALTER F W (CH); ZIMMER ROBERT H (C) 10 August 1995 "L": DOCUMENT SO QUOTED FOR ITS' CASTING DOUBT ON THE VALIDITY OF THE CONVENTION-PRIORITY CLAIM see the whole document --- -/--	1-12, 15-20, 22-27 13, 14, 21
X, Y, L  Y	WO 94 27557 A (SMITHKLINE BEECHAM CORP ;PALEPU NAGESWARA R (US); VENKATESH GOPADI) 8 December 1994 "L": DOCUMENT SO QUOTED FOR ITS' CASTING DOUBT ON THE VALIDITY OF MTHE CONVENTION-PRIORITY CLAIM see the whole document ---	1-5, 10-12, 17, 22-27 6-9, 13-16, 18-21



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

30 June 1998

Date of mailing of the international search report

08/07/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fischer, W

## INTERNATIONAL SEARCH REPORT

onal Application No

PCT/EP 98/00811

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 92 19227 A (BEECHAM LAB SA ; SMITHKLINE BEECHAM PLC (GB)) 12 November 1992 see the whole document ---	1-27
A	WO 95 28927 A (SMITHKLINE BEECHAM CORP ; SMITHKLINE BEECHAM PLC (GB); CONLEY CREIG) 2 November 1995 cited in the application ---	
A	WO 95 25516 A (SMITHKLINE BEECHAM PLC ; HATTON ANTHONY GUY (GB)) 28 September 1995 cited in the application ---	
A	GB 2 005 538 A (BEECHAM GROUP LTD) 25 April 1979 cited in the application ---	
A	WO 95 28148 A (SMITHKLINE BEECHAM PLC ; GRIMMETT FRANCIS WALTER (GB); DAVIDSON NIG) 26 October 1995 -----	



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/00811

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9520946 A	10-08-1995	EP 0742712 A JP 9509412 T	20-11-1996 22-09-1997
WO 9427557 A	08-12-1994	AU 684522 B AU 7096294 A CA 2164003 A CN 1124452 A EP 0701436 A JP 8510752 T US 5690959 A ZA 9403736 A	18-12-1997 20-12-1994 08-12-1994 12-06-1996 20-03-1996 12-11-1996 25-11-1997 08-03-1995
WO 9219227 A	12-11-1992	AP 328 A AU 659836 B AU 1649892 A BR 9205948 A CA 2102630 A CN 1067577 A CZ 9302379 A EP 0585252 A EP 0783889 A EP 0787487 A FI 934914 A HU 67020 A IL 101795 A JP 6507396 T MX 9202118 A NO 934009 A NZ 242625 A PT 100458 A SK 112793 A	23-03-1994 01-06-1995 21-12-1992 08-11-1994 09-11-1992 06-01-1993 16-03-1994 09-03-1994 16-07-1997 06-08-1997 05-11-1993 30-01-1995 16-10-1996 25-08-1994 01-03-1993 05-11-1993 26-08-1994 31-08-1993 08-06-1994
WO 9528927 A	02-11-1995	AP 564 A AU 684949 B AU 2406895 A BG 100933 A BR 9507502 A CA 2188496 A CN 1149829 A CZ 9603090 A	21-11-1996 08-01-1998 16-11-1995 31-07-1997 02-09-1997 02-11-1995 14-05-1997 16-04-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/00811

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9528927 A		EP 0758235 A EP 0761218 A FI 964249 A HU 76335 A JP 9512027 T NO 964488 A PL 316966 A SK 135496 A ZA 9503236 A	19-02-1997 12-03-1997 22-10-1996 28-08-1997 02-12-1997 17-12-1996 03-03-1997 07-05-1997 27-12-1995
WO 9525516 A	28-09-1995	EP 0751771 A JP 9510470 T	08-01-1997 21-10-1997
GB 2005538 A	25-04-1979	AU 525089 B AU 4050678 A BE 870988 A CA 1105385 A CH 642258 A DE 2843318 A FR 2405711 A HK 73785 A JP 1494273 C JP 54076831 A JP 63041886 B KE 3525 A NL 7810176 A,B SE 435899 B SE 7810591 A SE 451668 B SE 8107592 A US 4441609 A US 4301149 A ZA 7805682 A	21-10-1982 17-04-1980 03-04-1979 21-07-1981 13-04-1984 12-04-1979 11-05-1979 04-10-1985 20-04-1989 19-06-1979 19-08-1988 31-05-1985 17-04-1979 29-10-1984 11-04-1979 26-10-1987 17-12-1981 10-04-1984 17-11-1981 26-09-1979
WO 9528148 A	26-10-1995	EP 0752850 A JP 9511994 T	15-01-1997 02-12-1997